

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT**  
**THE CENTER FOR DRUG EVALUATION, NMPA GRANTED PRIORITY**  
**REVIEW STATUS TO NDA FOR DTCP INFANT**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated December 16, 2024 in relation to the notice of acceptance granted by the National Medical Products Administration of the People's Republic of China (the “**NMPA**”) to the Company's new drug application (the “**NDA**”) for its absorbed diphtheria, tetanus and acellular pertussis (components) combined vaccine (the “**DTcP**”) for infants (below 2 years old) (the “**DTcP Infant**”) developed by the Company.

The Company is pleased to announce that the Center for Drug Evaluation, NMPA granted priority review status to the Company's NDA for its DTcP Infant. According to the requirement of national priority review and approval, the Center for Drug Evaluation, NMPA will prioritize resource allocation for the review of NDAs included in the scope of priority review and approval.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, February 7, 2025

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.*